ARE CENTRAL HEMODYNAMIC PARAMETERS BETTER PROGNOSTIC MARKERS THAN PERIPHERAL BLOOD PRESSURE IN STROKE?

by Alberto Avolio, Ernesto L. Schiffrin
Published 2018-12-01

Reduction of C-reactive protein and the use of anti-hypertensives

by Carmine Savoia, Ernesto L Schiffrin
Published 2008-01-01

The angiotensin II type 2 receptor in cardiovascular disease

by Catherine A Lemarié, Ernesto L Schiffrin
Published 2010-03-01

Erratum to “Angiotensin II, Aldosterone, and Anti-Inflammatory Lymphocytes: Interplay and Therapeutic Opportunities”

by Daniel Arthur B. Kasal, Ernesto L. Schiffrin
Published 2012-01-01

Angiotensin II, Aldosterone, and Anti-Inflammatory Lymphocytes: Interplay and Therapeutic Opportunities

by Daniel Arthur B. Kasal, Ernesto L. Schiffrin
Published 2012-01-01

Review: ACE inhibition or angiotensin receptor blockade: which should we use in diabetic patients?

by Luis M Ruilope, Julian Segura, Ernesto L Schiffrin
Published 2003-06-01

Reduction of resistance artery stiffness by treatment with the AT1-receptor antagonist losartan in essential hypertension

by Jeong Bae Park, Hope D Intengan, Ernesto L Schiffrin
Published 2000-03-01

Long-term use of angiotensin receptor blockers and the risk of cancer.

by Laurent Azoulay, Themistocles L Assimes, Hui Yin, Dorothee B Bartels, Ernesto L Schiffrin, Samy Suissa
Published 2012-01-01

PROTECTIVE EFFECTS OF ANGIOTENSIN II BLOCKADE WITH OLMESARTAN MEDOXOMIL ON RESISTANCE VESSEL REMODELING

by Ronald D. Smith, Hiroshi Yokoyama, David B. Averill, Lori Cooke, K. Bridget Brosnihan, Ernesto L. Schiffrin, Carlos M. Ferrario
Published 2010-10-01

Hypertension in Canada: Past, Present, and Future

by Ernesto L. Schiffrin, Norman R.C. Campbell, Ross D. Feldman, Janusz Kaczorowski, Richard Lewanczuk, Raj Padwal, Sheldon W. Tobe
Published 2016-06-01

Gene expression in the vasculature of mice overexpressing human endothelin-1 in the endothelium

by Simeone, Stefania
Published 2010

Immune modulation in cardiovascular disease

by Shbat, Layla
Published 2011